AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2310093
Drug: Amiloride inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiloride inhalation
Trial: 466843
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group (n = 8)
Trial: 466843
Drug: Non-treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-treatment group (n = 10)
Trial: 25994910
Drug: Standard BFM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard BFM therapy
Trial: 25994910
Drug: Extended, usually
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended, usually more intensive experimental treatment
Trial: 19048458
Drug: GW9662 (PPARgamma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW9662 (PPARgamma antagonist) with benzbromarone
Trial: 19048458
Drug: GW9662 (PPARgamma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW9662 (PPARgamma antagonist) with pioglitazone
Trial: 16889452
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Sertraline and HRT
Trial: 11715490
Drug: E1 group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E1 group (esmolol 1 mg/kg)
Trial: 11715490
Drug: E2 group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2 group (esmolol 2 mg/kg)
Trial: 26246241
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (100,000 IU followed by 4,000 IU daily for 16 weeks)
Trial: 26246241
Drug: Placebo (identical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identical capsules for 16 weeks)
Trial: 18563688
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy with pemetrexed and cisplatin
Trial: 18563688
Drug: Chemotherapy in
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy in pretreated patients
Trial: 16630771
Drug: Orlistat (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat (120 mg 3 times daily for 6 months)
Trial: 12649866
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion titrated to a Bispectral Index near 80
Trial: 12649866
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion titrated to a Bispectral Index near 60
Trial: 7782484
Drug: Sertraline, 100
RxNorm normalized name: Sertraline, 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline, 100 mg
Trial: 7782484
Drug: Sertraline, 200
RxNorm normalized name: Sertraline, 200 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline, 200 mg
Trial: 7782484
Drug: Alprazolam, 1
RxNorm normalized name: Alprazolam, 1 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam, 1 mg
Trial: 7782484
Drug: Dextroamphetamine, 10
RxNorm normalized name: Amphetamine-Dextroamphetamine, 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextroamphetamine, 10 mg
Trial: 31465115
Drug: Single-injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-injection
Trial: 22537421
Drug: Target hemoglobin
RxNorm normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target hemoglobin level of 13.5 g/dL
Trial: 22537421
Drug: Target hemoglobin
RxNorm normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target hemoglobin level of 11.3 g/dL
Trial: 19666395
Drug: High-dose N-acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose N-acetylcysteine (2800 mg/daily)
Trial: 19666395
Drug: Low-dose N-acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose N-acetylcysteine (700 mg/daily)
Trial: 17490437
Drug: Open irrigation
RxNorm normalized name: BOTTLE OPENER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open irrigation tip (OIT) technology; temperature and power set at 50 degrees and 50 W, saline pump flow rate of 30 mL/min
Trial: 12010358
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy with adherence
Trial: 12010358
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy with non-adherence
Trial: 12010358
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy with adherence and nadir below limit
Trial: 12010358
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy with adherence and nadir above limit
Trial: 9820445
Drug: 1.1% amino
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.1% amino acid peritoneal dialysis solution (DAA)
Trial: 27497779
Drug: NSAID (Ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAID (Ibuprofen 1800mg/day)
Trial: 27497779
Drug: Healthy controls
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy controls (CRP<1mg/l)
Trial: 25600772
Drug: CHO/HAA (CHO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO/HAA (CHO + 13 g AA)
Trial: 25600772
Drug: CHO/LAA (CHO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO/LAA (CHO + 6.5 g AA)
Trial: 25600772
Drug: CHO (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO (1.2 g/kg body weight)
Trial: 23745309
Drug: 0.5-hour infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5-hour infusion of 0.5 g every six hours for 24 hours
Trial: 23745309
Drug: 2-hour infusion
RxNorm normalized name: Interleukin-2/diptheria toxin fusion protein
DrugBank: Denileukin diftitox (DB00004)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2-hour infusion of 0.5 g every six hours for 24 hours
Trial: 23745309
Drug: 2-hour infusion
RxNorm normalized name: Interleukin-2/diptheria toxin fusion protein
DrugBank: Denileukin diftitox (DB00004)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2-hour infusion of 1 g every six hours for 24 hours
Trial: 21420732
Drug: Azacitidine 50
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine 50 mg/m² thrice weekly for 2 weeks every 4 weeks
Trial: 21420732
Drug: Weekly erythropoietin
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly erythropoietin (in 7 patients)
Trial: 19335843
Drug: Biologic agents
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biologic agents (Tumor necrosis factor inhibitors, Alemtuzumab, Rituximab)
Trial: 19335843
Drug: Optimal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal therapy
Trial: 15283740
Drug: Antidepressant Compliance
RxNorm normalized name: ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Antidepressant Compliance Questionnaire (ADCQ)
Trial: 9313060
Drug: Ciprofloxacin 100
RxNorm normalized name: ciprofloxacin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 100 mg twice a day for 3 days
Trial: 9313060
Drug: Cotrimoxazol 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cotrimoxazol 8 mg and pipemidic acid 100 mg administered twice a day (control group)
Trial: 8497669
Drug: All solutions
RxNorm normalized name: ALCOHOL 0.57 mL in 1 mL / IODINE 0.06 g in 1 mL / POTASSIUM IODIDE 0.05 g in 1 mL / BORIC ACID 0.01 g in 1 mL / SODIUM BORATE 0.002 g in 1 mL TOPICAL LINIMENT [Ball Solutions]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All solutions
Trial: 24295873
Drug: Emtricitabine/Tenofovir combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emtricitabine/Tenofovir combination therapy
Trial: 24295873
Drug: Tenofovir monotherapy
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tenofovir monotherapy
Trial: 22654006
Drug: IBV Valves
RxNorm normalized name: AmproMed for Calves
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBV Valves (treatment group)
Trial: 18487900
Drug: Psychosocial support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychosocial support therapy (Control)
Trial: 10621925
Drug: Vinorelbine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine (30 mg/m2 on day 1 and day 8) and Cisplatin (100 mg/m2 on day 1) administered every three weeks
Trial: 28913735
Drug: Tazarotene 0.1%
RxNorm normalized name: TAZAROTENE 0.1% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tazarotene 0.1% plus Clindamycin 1% gel
Trial: 28913735
Drug: Adapalene 0.1%
RxNorm normalized name: ADAPALENE 0.1% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapalene 0.1% plus Clindamycin 1% gel
Trial: 24451122
Drug: Daclatasvir 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclatasvir 10 mg with peginterferon alfa-2b/ribavirin
Trial: 24451122
Drug: Daclatasvir 60
RxNorm normalized name: daclatasvir 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclatasvir 60 mg with peginterferon alfa-2b/ribavirin
Trial: 24451122
Drug: Daclatasvir 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclatasvir 10 mg for prior non-responders
Trial: 24451122
Drug: Daclatasvir 60
RxNorm normalized name: daclatasvir 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclatasvir 60 mg for prior non-responders
Trial: 22835054
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy (TG)
Trial: 22835054
Drug: Without thrombolytic
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Without thrombolytic therapy (WTG)
Trial: 22835054
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy (TG) and Without thrombolytic therapy (WTG)
Trial: 19378646
Drug: Multidimensional Family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidimensional Family Therapy HIV/STD risk-reduction intervention (MDFT-HIV/STD)
Trial: 17412790
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose supplementation (G)
Trial: 15054020
Drug: Housing First
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Housing First program (immediate housing without treatment prerequisites)
Trial: 15054020
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (housing contingent on treatment and sobriety)
Trial: 9462187
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (NO) for 72 hours
Trial: 9462187
Drug: Dexamethasone (0.5‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (0.5‐1 mg/kg/day intravenous for 6 days)
Trial: 9462187
Drug: Both inhaled
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both inhaled NO and dexamethasone
Trial: 7949804
Drug: 0.5 IU/kg/week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 IU/kg/week of recombinant human growth hormone for over one year
Trial: 2896219
Drug: Three-vial system
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-vial system (buffered glycerol saline, Cary‐Blair medium with campylobacter antibodies, and polyvinyl alcohol fixative)
Trial: 9989684
Drug: Test supplement
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test supplement
Trial: 23988010
Drug: Moderate alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moderate alcohol intake (5 to 15 g/day)
Trial: 17159759
Drug: Lidocaine 1
RxNorm normalized name: lidocaine 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 1 mL of 1% (10 mg) added to 100 mg of propofol
Trial: 17037821
Drug: Tianeptine (37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tianeptine (37.5 mg/day)
Trial: 9593759
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution (154 mmol liter-1 NaCl)
Trial: 8005273
Drug: Endometrial priming
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endometrial priming with oral micronized E2, 4 mg/d for 14 days; Progesterone replacement IM P in oil, 50 mg/d for 14 days.
Trial: 2680288
Drug: Bezafibrate (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bezafibrate (200 mg twice or 3 times a day)
Trial: 2680288
Drug: Probucol (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probucol (500 mg twice a day)
Trial: 30898253
Drug: Sirolimus-coated balloon
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus-coated balloon (SeQuent SCB, 4 μg/mm2)
Trial: 30898253
Drug: Paclitaxel-coated balloon
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel-coated balloon (SeQuent Please Neo, 3 μg/mm2)
Trial: 27189694
Drug: 6-mercaptopurine (6MP)
RxNorm normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6-mercaptopurine (6MP) medication adherence
Trial: 27189694
Drug: Behavioral adherence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral adherence measures (e.g., electronic monitoring)
Trial: 19372653
Drug: Terutroban 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terutroban 30 mg/day
Trial: 15353532
Drug: Galantamine hydrobromide
RxNorm normalized name: Galantamine Hydrobromide
DrugBank: Galantamine (DB00674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Galantamine hydrobromide 2.5 mg
Trial: 15353532
Drug: Galantamine hydrobromide
RxNorm normalized name: Galantamine Hydrobromide
DrugBank: Galantamine (DB00674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Galantamine hydrobromide 5.0 mg
Trial: 15353532
Drug: Galantamine hydrobromide
RxNorm normalized name: Galantamine Hydrobromide
DrugBank: Galantamine (DB00674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Galantamine hydrobromide 7.5 mg
Trial: 15353532
Drug: Galantamine hydrobromide
RxNorm normalized name: Galantamine Hydrobromide
DrugBank: Galantamine (DB00674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Galantamine hydrobromide 10 mg
Trial: 2605069
Drug: Cimetidine 1600
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine 1600 mg orally before anaesthesia
Trial: 2605069
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets before anaesthesia
Trial: 16151033
Drug: Clopidogrel with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel with aspirin (C+ASA)
Trial: 7741782
Drug: Amoxicillin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (250 mg) plus bromhexine (8 mg) (Drug AB)
Trial: 24154820
Drug: Prosure (specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prosure (specific supplement enriched with n-3 polyunsaturated fatty acids, fiber, proteins, and electrolytes)
Trial: 24154820
Drug: Standard-Isosource (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-Isosource (standard supplement)
Trial: 12673176
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of I‐123 MIBG heart‐mediastinal ratio and HRV 5‐minute low‐frequency variables
Trial: 27179988
Drug: Aspirin (325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (325 mg loading dose followed by 81 mg/d)
Trial: 20592433
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (400 mcg/d) + vitamin B12 (100 mcg/d)
Trial: 18588848
Drug: Misoprostol 400
RxNorm normalized name: Misoprostol 400 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol 400 microg administered vaginally twice, 6 and 12 hours before hysteroscopy
Trial: 18588848
Drug: Placebo (hexetidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (hexetidine pill) administered vaginally twice, 6 and 12 hours before hysteroscopy
Trial: 16087019
Drug: Injection snoreplasty
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection snoreplasty (IS)
Trial: 12544159
Drug: Home interferential
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home interferential current therapy (IFC)
Trial: 10479130
Drug: Protease inhibitor-containing
RxNorm normalized name: Protease inhibitor-containing product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protease inhibitor-containing triple therapy for 2 years
Trial: 1891022
Drug: Controlled-release aspirin
RxNorm normalized name: aspirin Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release aspirin (75 mg, releasing 10 mg per hour)
Trial: 1891022
Drug: Immediate-release aspirin
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate-release aspirin (162.5 mg loading dose)
Trial: 1891022
Drug: Immediate-release aspirin
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate-release aspirin (75 mg)
Trial: 1891022
Drug: Controlled-release aspirin
RxNorm normalized name: aspirin Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release aspirin (75 mg)
Trial: 6215855
Drug: Bound niacin
RxNorm normalized name: Niacin
DrugBank: Niacin (DB00627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bound niacin (BN) - 35 mg niacin
Trial: 6215855
Drug: Alkali-treated bound
RxNorm normalized name: alkali blite pollen extract
DrugBank: Suaeda moquinii pollen (DB10953)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alkali-treated bound niacin (ABN) - 24 mg pure nicotinic acid
Trial: 6215855
Drug: Nicotinic acid
RxNorm normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotinic acid - 24 mg
Trial: 28847468
Drug: slow‐release melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: slow‐release melatonin at a dose of 3mg
Trial: 24477842
Drug: Toothpaste B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toothpaste B (0.454% SnF2, Oral-B(®))
Trial: 24477842
Drug: SnF2 solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SnF2 solution (0.4%, 1,000 ppm F)
Trial: 20363764
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg clopidogrel loading 4-8 hours before PCI
Trial: 16116130
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid drink containing l-tryptophan
Trial: 16116130
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid drink omitting l-tryptophan
Trial: 8918516
Drug: Al(OH)3 (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Al(OH)3 (one tablet three times a day, about 302 mg aluminium day‐1) for 3 months
Trial: 8918516
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (20 patients receiving no Al‐containing agents)
Trial: 1907681
Drug: phenytoin suspension
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: phenytoin suspension alone
Trial: 6440313
Drug: Gliclazide 40
RxNorm normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gliclazide 40 mg
Trial: 6440313
Drug: Glibenclamide 2.5
RxNorm normalized name: glibenclamide 2.5 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glibenclamide 2.5 mg
Trial: 30807455
Drug: Observational treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observational treatment
Trial: 30807455
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (Antibiotic and Observational)
Trial: 29968187
Drug: Adequate vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adequate vitamin D group (AVD; serum 25(OH)D > 50 nmol/l)
Trial: 29968187
Drug: Inadequate vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inadequate vitamin D group (IVD; serum 25(OH)D < 50 nmol/l)
Trial: 26889974
Drug: Intermittent chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent chemotherapy
Trial: 26889974
Drug: Continuous chemotherapy
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous chemotherapy
Trial: 22960817
Drug: Permethrin 5%
RxNorm normalized name: PERMETHRIN 5% CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Permethrin 5% cream as single application
Trial: 22960817
Drug: Topical ivermectin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ivermectin 1% lotion as single application